The United States CDMO market was valued at USD 86.11 Billion in 2025, driven by the rising prevalence of chronic diseases such as asthma and diabetes, and the growing demand for biologics and advanced therapeutics across the region. The market is anticipated to grow at a CAGR of 10.70% during the forecast period of 2026-2035, with the values likely to reach USD 237.97 Billion by 2035.
Base Year
Historical Period
Forecast Period
As of 2022, an estimated 24.4 million people in the United States had been diagnosed with diabetes, highlighting a significant public health burden and emphasizing the need for improved prevention and management strategies.
Recent product approvals and innovative treatment solutions, such as advanced insulin delivery systems and digital monitoring tools, are significantly enhancing diabetes care and driving growth in therapeutic and management markets.
Strategic partnerships and acquisitions among major healthcare and technology firms are shaping the diabetes landscape, reflecting a strong trend toward integrated care solutions and expanding access to personalized treatment approaches.
Compound Annual Growth Rate
10.7%
Value in USD Billion
2026-2035
*this image is indicative*
The CDMO market plays a crucial role in supporting the pharmaceutical and biotechnology sectors by offering integrated solutions that enhance efficiency and scalability. As companies increasingly rely on external partners to manage complex development and production processes, the market continues to expand. Growth is fueled by rising demand for biologics, advanced therapies, and flexible manufacturing capabilities. With strong regulatory alignment, modern infrastructure, and growing R&D investments, the market is projected to grow at a CAGR of 10.70% during 2026–2035.
One of the key growth drivers is the increasing burden of chronic diseases, particularly respiratory illnesses like asthma. According to the 2024 Asthma Capitals Report, nearly 28 million Americans were living with asthma as of 2024, approximately 1 in 12 individuals. As a result, the need for efficient, scalable production of respiratory drugs and delivery devices is accelerating. CDMOs offer the necessary infrastructure, regulatory expertise, and flexibility to support pharmaceutical companies in developing and producing inhalation therapies and biologics. This persistent health burden underlines the role of CDMOs in supporting innovation and supply in the chronic disease treatment space, boosting market growth in the years ahead.
Another significant growth driver is the surge in biologics development and the strategic investments being made to meet this rising demand. For instance, in June 2025, Zydus Lifesciences Ltd. announced its entry into the global biologics CDMO business through the acquisition of Agenus Inc.’s manufacturing facilities in California. This move marks a notable shift, as international companies increasingly seek United States-based production to serve global biotech clients more efficiently. With cutting-edge capabilities in biologics development and manufacturing, Zydus’ investment strengthens the CDMO ecosystem in the United States. The deal highlights the country's position as a key hub for biologics and underscores the critical role of CDMOs in enabling innovation and ensuring rapid, compliant production pipelines.
The market is witnessing several trends, including a surge in strategic acquisitions.
Surging Strategic Acquisitions Likely to Boost United States CDMO Market Value
A notable trend in the United States CDMO market is the rising number of strategic acquisitions, aimed at expanding capabilities and global reach. For instance, in December 2024, Arterex acquired Phoenix S.r.l., a leading Italian CDMO offering MDR-compliant design, assembly, and packaging services. This move strengthens Arterex’s position in regulated markets. Such strategic consolidations are expected to significantly enhance the market’s growth trajectory in the coming years.
Oncology to Lead the Segmentation Based on Therapeutic Areas
The CDMO market serves a wide range of therapeutic areas, including oncological diseases, metabolic disorders, neurological disorders, respiratory diseases, cardiovascular diseases, infectious diseases, and others. Oncology is expected to lead the market, driven by rising cancer incidence, robust R&D investments, and government reimbursement policies. According to Rebecca L. Siegel, MPH et al., 2025, 2,041,910 new cancer cases are projected in 2025 in the United States, underscoring sustained demand for oncology-focused CDMO services.
The report covers the United States regions, including New England, the Mideast, the Great Lakes, the Plains, the Southeast, the Southwest, the Rocky Mountain, and the Far West. Among these, the Far West, especially California and Washington, is expected to demonstrate significant growth. This region benefits from high levels of pharmaceutical and biotech activity, extensive clinical trial pipelines, and major CDMO facility investments. As operators expand manufacturing capabilities and leverage innovation hubs, regional growth momentum is anticipated to remain strong.
The United States CDMO market research report by Expert Market Research provides an in-depth analysis of the competitive landscape, offering key insights into patent filings, grants, funding trends, investments, and strategic initiatives by major players. It tracks recent investments, mergers, acquisitions, and partnerships that showcase the market's growth trajectory. Additionally, the report details strategic activities by leading companies, including regional expansions, adoption of new technologies, and efforts to enhance capacity, helping stakeholders better understand the market dynamics and positions of key industry players. Some of the leading players are as follows:
Vetter is a leading global CDMO specializing in aseptic fill-and-finish services, offering end-to-end solutions from clinical development to commercial production. The company generates good sales through its sterile injectable manufacturing capabilities. With a strong presence in the United States, Vetter supports pharmaceutical clients through advanced drug product development, aseptic filling, device assembly, analytical services, and regulatory compliance assistance.
Recipharm offers end-to-end CDMO services spanning oral solids, sterile fill-finish, and biologics. In October 2024, through a strategic alliance with Exela Pharma Sciences in North Carolina, they now have capacity for over 100 million vials and pre-filled syringes annually, including biologics, ADCs, GLP‑1 drugs, and vaccines. They also deployed a new modular Grade A sterile filling line in Germany, supporting syringes, vials, and PFS, helping biotech clients from development to clinical production
Under Thermo Fisher, Patheon provides comprehensive CDMO services across the United States, including small-molecule APIs, biologics, viral vectors, and clinic-to-commercial fill-finish (vials, ampoules, PFS). Its robust capabilities in both oral solids and sterile injectables support major pharma and biotech clients such as Amgen, Novartis, and Merck. On-site product listings showcase services for cGMP plasmids and viral vectors, emphasizing flexibility across development stages
Pfizer Inc., through its specialized CDMO division Pfizer CentreOne, plays a significant role in the United States CDMO market. Leveraging Pfizer’s advanced global manufacturing network, the company offers comprehensive development and commercial manufacturing services for oral solids, sterile injectables, biologics, and small molecule APIs. With integrated regulatory support and end-to-end lifecycle services, Pfizer CentreOne enables pharmaceutical and biotech partners to bring high-quality therapies to market efficiently.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Boehringer Ingelheim, Famar SA, Lonza Group, Novotech Pty Ltd., WuXi AppTec, Fareva SA, FUJIFILM Diosynth Biotechnologies, Nipro Pharma Corporation, B. Braun SE, and WuXi Biologics.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Service Type
Market Breakup by Therapeutic Area
Market Breakup by End User
Market Breakup by Region
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Service Type |
|
| Breakup by Therapeutic Area |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share